Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevalence and course of arthritis and enthesitis in psoriasis, and effect of apremilast in subclinical psoriatic arthritis
2016-004354-15Phase 4Terminated
- Sponsor
- Rigshospitalet
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of apremilast in psoriasis and psoriatic arthritis (PsA), sponsored by Rigshospitalet. Primary endpoint: Prevalence and pattern of arthritis and enthesitis in psoriasis (Part 1). Started Oct 2017; status: terminated.
02
Drugs
apremilast
03
Conditions
psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2016-004354-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004354-15.